Cohort characteristics | No. (%) | |
---|---|---|
N = 143 | ||
GIK (N = 68) | Placebo (N = 75) | |
Age, mean (SD), y | 64.5 (12.9) | 63.9 (12.8) |
Men | 52 (76.5) | 52 (69.3) |
Race | Â | Â |
 White | 66 (97) | 71 (95) |
Hispanic ethnicity | 3 (4.4) | 7 (9.3) |
Chief complaint on presentation | Â | Â |
 Chest pain | 59 (86.8) | 67 (89.3) |
 Shortness of breath | 1 (1.5) | 3 (4) |
 Other b | 8 (11.7) | 5 (6.7) |
Medical history | Â | Â |
 Diabetes | 12 (17.6) | 19 (25.3) |
 Heart Failure | 4 (5.9) | 7 (9.3) |
 AMI | 21 (30.9) | 24 (32.0) |
Medication history | Â | Â |
 Statins | 30 (44.1) | 29 (38.7) |
 Aspirin | 39 (57.3) | 44 (58.7) |
Minutes from symptom onset to study drug, median (IQR) | 86 (51.5–160.5) | 81 (53–123) |
Minutes from symptom onset to study drug | ||
 0–30 | 1 (1.5) | 0 (0) |
 31–60 | 21 (30.9) | 22 (29.3) |
 61–90 | 9 (13.2) | 19 (25.3) |
 91–180 | 12 (17.7) | 15 (20.0) |
 181–360 | 10 (14.7) | 8 (10.7) |
 361–24 h | 6 (8.8) | 5 (6.7) |
 Within 24 h, unspecified | 3 (4.4) | 4 (5.3) |
>24Â h | 6 (8.8) | 2 (2.7) |
ACI-TIPI score, mean (SD), % | 83 (15.7) | 83.1 (12.1) |
Hospital reperfusion treatment | Â | Â |
 Thrombolytic therapy | 1 (1.5) | 1 (1.3) |
 PCI | 59 (86.8) | 56 (74.7) |
 Coronary artery bypass graft | 0 (0) | 2 (2.7) |
Confirmed diagnosis | Â | Â |
 Acute myocardial infarction | 58 (85.3) | 68 (90.7) |
 Any angina | 10 (14.7) | 7 (9.3) |
Time from study drug to biomarker measurement, median (IQR), hours | Â | Â |
 Initial | 2.5 (1.3–3.3) | 2.6 (1.9–3.2) |
 6 h | 6 (6–6.3) | 6 (6–6.2) |
 12 h | 12 (12–12.2) | 12.1 (12–12.3) |